From Scientific Insight to Clinical Results – the IL-17A & IL-17F Inhibiting Nanobody® Sonelokimab in Hidradenitis Suppurativa
Time: 2:00 pm
day: Conference Day Two
Details:
- Unravelling the pathophysiology of HS lesions – evidence for a role of IL-17F in HS inflammatory lesions
- Why penetration matters – new concepts around immune hotspots in inflammatory skin diseases
- Translational validation – clinical data from a phase 2 study of the IL-17A and IL-17F inhibiting Nanobody® sonelokimab in HS
